CDXS CODEXIS, INC.
Industrial Organic Chemicals · Nasdaq · SEC CIK 1200375 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY66.9%
TTM net income YoY69.9%
TTM EPS YoY75.3%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-18.3%
Net margin-21.8%
FCF margin-13.7%
EBITDA margin-12.6%
Returns
ROE-42.9%
ROA-14.3%
ROIC (approx.)-22.0%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets64.5%
Debt / equity0.81x
Current ratio2.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $70.39M | $59.34M | $70.14M | $138.59M | $104.75M |
| Cost of revenue | $9.34M | $16.29M | $12.81M | $38.03M | $22.21M |
| Gross profit | $61.05M | $43.06M | $57.33M | $100.56M | $82.55M |
| R&D expense | $52.31M | $46.26M | $58.88M | $80.10M | $55.92M |
| SG&A expense | $47.07M | $55.15M | $53.25M | $52.17M | $49.32M |
| Operating income | -$41.74M | -$58.52M | -$68.07M | -$34.88M | -$22.70M |
| Pretax income | -$43.93M | -$65.24M | -$76.17M | -$33.32M | -$21.09M |
| Income tax | $47,000 | $34,000 | $69,000 | $276,000 | $189,000 |
| Net income | -$43.97M | -$65.28M | -$76.24M | -$33.59M | -$21.28M |
| EBITDA | -$36.49M | -$53.57M | -$62.55M | -$29.48M | -$19.58M |
| EPS (basic) | -0.50 | -0.89 | -1.12 | -0.51 | -0.33 |
| EPS (diluted) | -0.50 | -0.89 | -1.12 | -0.51 | -0.33 |
| Weighted avg. shares (diluted) | 87.14M | 73.41M | 68.13M | 65.34M | 64.57M |
| Balance sheet | |||||
| Cash & equivalents | $50.79M | $20.83M | $65.12M | $116.03M | $118.89M |
| Short-term investments | $27.42M | $54.19M | $0 | — | — |
| Receivables | — | — | $10.04M | $31.90M | $24.95M |
| Inventory | $1.82M | $1.80M | $2.69M | $2.03M | $1.16M |
| Current assets | $96.82M | $98.77M | $93.47M | $162.89M | $161.89M |
| PP&E, net | $13.02M | $14.20M | $15.49M | $22.61M | $21.34M |
| Goodwill | $2.46M | $2.46M | $2.46M | $3.24M | $3.24M |
| Total assets | $147.80M | $149.01M | $136.56M | $250.39M | $246.38M |
| Current liabilities | $25.32M | $23.65M | $35.83M | $49.07M | $33.37M |
| Short-term debt | $0 | — | — | — | — |
| Long-term debt | $40.10M | $28.91M | $0 | — | — |
| Total debt | $40.10M | $28.91M | $0 | — | — |
| Total liabilities | $97.27M | $82.08M | $49.95M | $105.60M | $81.99M |
| Shareholders' equity | $50.53M | $66.93M | $86.61M | $144.80M | $164.39M |
| Net debt | -$10.69M | $8.08M | -$65.12M | — | — |
| Shares outstanding | 90.48M | 81.85M | 69.91M | 65.81M | 65.11M |
| Cash flow statement | |||||
| Operating cash flow | -$19.38M | -$49.41M | -$52.64M | $11.28M | -$14.27M |
| Capital expenditure | $4.47M | $4.30M | $4.42M | $8.31M | $13.83M |
| Free cash flow | -$23.85M | -$53.72M | -$57.06M | $2.98M | -$28.09M |
| Investing cash flow | $23.50M | -$56.98M | -$4.86M | -$13.58M | -$21.42M |
| Financing cash flow | $27.93M | $60.52M | $8.17M | -$575,000 | $3.77M |
| Depreciation & amortization | $5.25M | $4.95M | $5.52M | $5.40M | $3.11M |
| Stock-based compensation | $9.62M | $13.09M | $9.97M | $14.53M | $11.59M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.